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the best among this patient population. The Medicare and VGNW models
both showed good discrimination.
Fig. ROC curves of VSGNE predicting mortality after elective
AAA versus established risk prediction models.
Table. In-hospital mortality after elective AAA: Parsimonious 0.5 level
(C ¼ 0.812)
Odds ratio Conﬁdence limitVariable PAdjusted Lower UpperOpen infrarenal/above one
renal clamp vs endo3.8700 2.0485 7.3112 <.0001Open above both renals/
supraceliac clamp vs endo8.6776 4.3051 17.4910 <.0001Age 1.0790 1.0368 1.1228 .0002
Female vs male 1.7280 1.0023 2.9794 .0491
Body mass index 0.9749 0.9260 1.0264 .3337
Current smoking: yes vs no 0.6942 0.3065 1.5720 .3814
Myocardial disease 1.7219 1.0019 2.9593 .0492
Cerebrovascular disease 2.0902 0.9933 4.3984 .0521
Congestive heart failure 1.7298 0.8520 3.5122 .1294
Chronic obstructive pulmonary
disease
2.4737 1.4262 4.2905 .0013Creatinine 1.3210 0.9575 1.8225 .09Long-Term Surveillance of EVAR Patients With Ultrasound is Safe
and Effective
William C. Wu, MD, Raymond Eid, MD, Robert Hacker, MD, Michel S.
Makaroun, MD, Rabih A. Chaer, MD. University of Pittsburgh Medical
Center, Pittsburgh, Pa
Objectives: Color ﬂow duplex ultrasound (CDU) surveillance is an
accepted alternative to computed tomography (CT) after endovascular
repair of abdominal aortic aneurysms (EVAR). However, the long-term
effectiveness and safety of yearly CDU-only surveillance is not yet well
deﬁned. The purpose of this study was to evaluate the safety and effective-
ness of CDU follow-up in the long-term.
Methods: Patients who underwent EVAR between January 1, 2005,
and December 31, 2010, with no routine CT after 1 year and followed up
with CDU as the primary surveillance method for at least 2 years, were
included. Subsequent CT scans were only selectively obtained for enlarging
sac size or suspected type I or III endoleak. The majority of type II endo-
leaks were monitored with CDU only.Results: Reviewed were 169 patients switched to CDU follow-up
no later than 1 year after EVAR and followed up for 2 to 8 years, with
a mean of 4.5 6 1.3 years (53.6 6 16.1 months). They included two pa-
tients with limb infolding treated with extra stent grafts and 26 patients
with known prior endoleaks detected during the ﬁrst year, with two
type IB and one type II endoleaks already treated. During CDU follow-
up, 27 patients were identiﬁed to have a new endoleak, seven of whom
required a total of eight reinterventions with endovascular stent graft
extension or coiling, four after a conﬁrmatory CT and four without.
One patient with a renal artery stenosis at 3 years underwent angiography
and was found to have a renal artery occlusion caused by a barb fracture
and migration without endoleak. Only six patients underwent a CT to
further evaluate ﬁndings on CDU. There were no ruptures, limb occlu-
sions, or abdominal aortic aneurysm-related deaths throughout the
follow-up period.
Conclusions: After the 1-year postoperative CT, a switch to CDU as
the primary means of follow-up is a safe and effective surveillance strategy
after EVAR.
Comparative Safety of Endovascular and Open Surgical Repair of
Abdominal Aortic Aneurysms in Low-Risk Patients
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Andrew J. Meltzer, MD. Weill Cornell Medical College, New York, NY
Objectives: The prevalence of signiﬁcant comorbidities among pa-
tients with abdominal aortic aneurysms (AAAs) has contributed to wide-
spread enthusiasm for endovascular AAA repair (EVAR). However, the
advantages of EVAR in patients at low risk for open surgical repair (OSR)
remain unclear. Our objective was to compare perioperative outcomes of
EVAR vs OSR in low-risk patients.
Methods: Patients undergoing EVAR or OSR for infrarenal AAA
were identiﬁed in the 2007 to 2010 National Surgical Quality Improvement
Program data sets. AAA-speciﬁc risk stratiﬁcation, using the Medicare Aneu-
rysm Score (MAS), was used to create matched low-risk (MAS <3) cohorts.
Perioperative morbidity and mortality were assessed via crude comparisons
of matched groups and regression models.
Results: Of 11,753 patients undergoing EVAR, 4339 (37%) were
deemed low risk (MAS <3). A matched cohort of 1576 low-risk pa-
tients was developed from 3804 (41%) undergoing OSR. By deﬁnition,
the low-risk cohorts included only males aged <75 years without signif-
icant cardiac, pulmonary, or vascular comorbidities. Mean age in both
low-risk groups was 67 6 6 years (P ¼ not signiﬁcant). EVAR patients
were more likely to be obese (40.8% vs 30.4%; P < .001), diabetic
(16.2% vs 13.1%; P ¼ .005), and have a history of cardiac intervention
(24.3% vs 19.2%; P < .001), or surgery (22.6% vs 19.7%; P ¼ .02), ste-
roid use (3.6% vs 2.0%; P ¼ .002), and bleeding disorders (8.7% vs
5.9%; P ¼ .001). There were no other differences between the matched
cohorts. EVAR was associated with reduced 30-day mortality (0.6% vs
1.5%; P < .01) and reduced rates of major complications, including
sepsis (0.7% vs 3.2%; P < .01), unplanned intubation (1.0% vs 5.4%;
P < .001), pneumonia (0.8% vs 6.1%; P < .001), acute renal failure
(0.4% vs 2.7%; P < .001), and early reoperation (3.7% vs 6.0%), p 4
units (2.0% vs 13.0%; P < .001), cardiac arrest (0.2 vs 0.8;
P ¼ .001), neurologic deﬁcits (0.2% vs 0.5%; P ¼ .032), and urinary
tracts infections (1.2% vs 2%; P ¼ .02).
Conclusions: Our results demonstrate that even among those pa-
tients at low risk for OSR, EVAR is associated with reduced periopera-
tive mortality and major complications. Although clinical decisions
must account for safety and long-term effectiveness, the short-term
beneﬁt of EVAR is evident even among patients at the lowest risk for
OSR.
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Objectives: Conventional wisdom holds that patients with need for
intervention at a younger age have more aggressive disease, although there
is a paucity of supportive literature. The purpose of this study is to evaluate
this assumption.
Methods: A retrospective cohort of patients undergoing endovascu-
lar or open revascularization for femoropopliteal occlusive disease
(FPOD) over a 4-year period was assembled. Demographic information,
comorbidities, disease characteristics, and time to last follow-up or death
were recorded. Time to major revascularization or amputation or major
Table. Differences in disease severity, signiﬁcant comorbidities, and
outcomes on univariate analysis
Variable
#54 years
(n ¼ 57), %
55-74 years
(n ¼ 111), %
$75 years
(n ¼ 61), % P
Rutherford class 5 21.8 25.5 41.8 .05
Critical limb ischemia 48.2 49.5 71.7 .009
Open procedure 66.7 78.4 60.7 .04
History of smoking 69.2 72.3 43.4 .002
Quit smoking 15.4 34.1 24.5 .04
Secondary
revascularization
43.9 37.7 18.0 .004
Amputation 28.1 10.8 21.7 .02
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570 Abstracts February 2014adverse limb event (MALE) was also recorded. The patients were strati-
ﬁed by age into three groups: the youngest quartile, the oldest quartile,
and the middle two quartiles. Univariate and multivariate methods were
used to analyze the data.Results: There were 229 patients in the cohort representing a total
of 206,925 days of follow-up. The mean age was 64.5 6 0.85 years. The
overall mean time to MALE or death was 1216.8 6 85.9 days. The
younger group was #54 years old (n ¼ 57), the middle group was 55
to 74 years old (n ¼ 111), and the older group was $75 years old (n
¼ 61). Signiﬁcant ﬁndings on univariate analysis (Table) included more
severe disease at presentation in the older age group and a higher pro-
portion of secondary revascularization and amputation in the younger
group. A Kaplan-Meier curve to MALE or death approached signiﬁcance
(P ¼ .06), with a median time to event for the younger, middle, and
older groups of 253, 1083, and 865 days, respectively. A Cox regression
model was constructed, and age group was not signiﬁcantly correlated
with time to MALE or death (P ¼ .57) when controlling for
confounders.
Conclusions: These data refute the common assumption that
younger patients in need of intervention for FPOD have more aggressive
disease. It is the older population that has more severe disease before inter-
vention, and although on univariate analysis they have a lower proportion of
amputation and secondary revascularization, this is confounded by a higher
rate of death in this population. The younger cohort has a longer life expec-
tancy, and as such. a longer timer period during which reintervention may
be required.
